CIOReview
CIOREVIEW >> Pharma & life sciences >>

Document Security System Shows Decrease in COVID-19 Viral Population Using 3F Biofragrance

By CIOReview | Friday, September 25, 2020

Document Security Systems, Inc. has announced the study related tothe COVID-19 viral population.

FREMONT, CA: Document Security Systems, Inc. is a multinational organization operating a business. It focuses on technologies related to brand protection, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets. In recent times, the company has announced its wholly-owned subsidiary Impact BioMedical, Inc., with the help of its subsidiary Global BioLife, Inc., completed the efficiency testing of its patented 3F Antiviral Biofragrance at a biosafety level 3 containment facility at an independent university. Furthermore, the study explains about a 10-fold reduction in COVID-19 viral population on surfaces using 3F Biofragrance.

According to Daryl Thompson, Global BioLife's Director of Scientific Initiatives and founder of advanced research company GRDG Sciences, LLC ("GRDG"), "We are extremely excited with the results of the study, which was based on a quantifiable, robust model and designed to treat high levels of the COVID-19 virus.As the world continues to battle COVID-19, common antimicrobial compounds have the potential to be overused, leading to new health concerns. We designed 3F Biofragrance to solve this issue through a multi-focal approach to inhibiting viruses that reduces the chances of developing resistance as seen with other antimicrobials."

3F Biofragrance has been designed for the Open Air Defense Initiative. It was a strategy that can protect locations where vast numbers of people gather or transit like airports, containment areas, train stations, convention centers, hospitals, and ports of entry. Open Air Defense Initiative was developed as a solution for Event 201. The Johns Hopkins Center for Health Security, the World Economic Forum, and the Bill and Melinda Gates Foundation conducted this pandemic exercise in 2019. Event 201 emphasized the areas where it is necessary for the public or private partnerships so that they can respond to a severe pandemic. Other than COVID-19, 3F Biofragrance is also operative against E. coli, MRSA, Influenza, Rhinovirus, and Tuberculosis.

Thompson further stated, "3F Biofragrance has the potential to transform typical consumer products into weapons against the spread of COVID-19 and other viruses, and we look forward to providing updates on ongoing negotiations for global licensing and royalty agreements of this innovative technology."